Immuno-Oncology

Nivolumab (Opdivo) improved quality of life scores in most patients with head and neck squamous cell carcinoma (HNSCC).

The Insitute for Clinical Immuno-Oncology (ICLIO) are supporting multidisciplinary cancer teams to better deliver new and emerging cancer therapies.

Pembrolizumab (Keytruda) has been granted accelerated approval for certain solid tumors.

The FDA has granted approval to pembrolizumab (Keytruda) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with non-small cell lung cancer (NSCLC).

Rajni Kannan, BS, MS, RN, APN-BC, discusses the management of patients receiving combination immunotherapy.

The FDA has granted accelerated approval to avelumab (Bavencio) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Nurses at Smilow Cancer Hospital leveraged their electronic medical record system to improve care and management of patients receiving immunotherapies.

While patients with stage III or IV melanoma who received a higher dose of ipilimumab did live longer than those on a lower dose, there was also greater toxicity.

Jose Lutzky, MD, discusses the importance of proactive patient monitoring with patients receiving immunotherapy treatments.

A recent study has found that pembrolizumab (Keytruda) may be effective in treating patients with mesothelioma.

An ongoing trial is evaluating the combination therapy of interleukin-10 agonist AM0010 and FOLFOX chemotherapy, for patients with metastatic pancreatic cancer.

Richard Carvajal, MD, discusses the importance of a multidisciplinary approach when monitoring patients for immunotherapy toxicities.

After chemotherapy proved unsuccessful, one patient entered a clinical trial of a new combination for immunotherapy for her ovarian cancer.

For patients with non-small cell lung cancer (NSCLC) receiving pembrolizumab, long-term survival rates could reach 25%.

A recent study presented at the 2017 Genitourinary Cancers Symposium found that use of antibiotics could damper the efficacy of checkpoint inhibitors, potentially due to the relationship between gut microbiota and antibiotics.

Some patients with metastatic rena cell carcinoma (mRCC) exhibited sustained responses even up to 6 months of being off the immunotherapy treatment.

Richard Carvajal, MD, discusses how to make decisions regarding the dosing limits of immunotherapy agents.

The American Society of Clinical Oncology named Immunotherapy 2.0 as the Advance of the Year, as it continues to move the cancer field forward.

Claire Friedman discusses the factors clinicians should consider when determining an immunotherapy treatment plan for older patients.

Laura Wood on collaboration between departments when treating patients with cancer who are receiving immunotherapy treatments.

Karen Lee explains why it is important for patients to understand immunotherapy and how nurses can help them in patients education.

Immunotherapy agents are drastically changing the treatment landscape – and outcomes – of patients with head and neck cancers.

Nurse practitioner Brianna Hoffner, MSN, NP, RN, discusses the important things to consider for an oncology nurse working with patients being treated with cancer immunotherapies.

Lisa Butterfield discusses what nurses should know when treating patients receiving immunotherapies.

Alex Herrera discusses the response of patients with Hodgkin lymphoma on combination nivolumab/brentuximab vedotin.

Igor Puzanov discusses the rare cardiologic adverse events that can occur when a patient is on checkpoint inhibitors.

Elizabeth Repasky discusses chronic stress and its link to anti-tumor immune reponses.

Christian Capitini discusses the responses to immunotherapy.